argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy
Portfolio Pulse from Benzinga Newsdesk
argenx SE has announced its plan to advance to a second dose cohort with the Phase 2 ARDA study of empasiprubart (ARGX-117) in multifocal motor neuropathy (MMN) following a planned interim analysis by an Independent Data Monitoring Committee.
June 20, 2023 | 7:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
argenx's advancement to the second dose cohort in the Phase 2 ARDA study of empasiprubart may positively impact the company's stock price.
The advancement to the second dose cohort in the Phase 2 ARDA study of empasiprubart indicates positive progress in the clinical trial. This may lead to increased investor confidence in the company's potential to develop a successful treatment for multifocal motor neuropathy, which could positively impact argenx's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100